Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM260KD)

Drug Name
5-CT Drug Info
Synonyms 5-carboxamidotryptamine
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
1809
ChEBI ID
CHEBI:48292
CAS Number
CAS 74885-09-9
TTD Drug ID
DM260KD

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Patented Agent(s)
Discontinued Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting 5-HT 1B receptor (HTR1B)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [13]
Eletriptan DMW649X Migraine 8A80 Approved [14]
Zolmitriptan DM1IB4Q Migraine 8A80 Approved [14]
Frovatriptan DM7RE8P Migraine 8A80 Approved [14]
Fluphenazine DMIT8LX Psychotic disorder 6A20-6A25 Approved [14]
Naratriptan DMO50U2 Migraine 8A80 Approved [15]
Prolixin decanoate DMMJ1IS Schizophrenia 6A20 Approved [14]
Eltoprazine DMW6C81 Attention deficit hyperactivity disorder 6A05.Z Phase 3 [16]
NXN-188 DMMBAIH Migraine 8A80 Phase 2 [17]
[N-methyl-3H(3)]AZ-10419369 DMSCV02 Mood disorder 6A60-6E23 Phase 1 [18]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 1D receptor (HTR1D)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [4]
Eletriptan DMW649X Migraine 8A80 Approved [14]
Zolmitriptan DM1IB4Q Migraine 8A80 Approved [14]
Frovatriptan DM7RE8P Migraine 8A80 Approved [14]
Sumatriptan DMVYXR8 Migraine 8A80 Approved [19]
Rizatriptan DMDJMA3 Migraine 8A80 Approved [20]
Almogran DM7I64Z Migraine 8A80 Approved [21]
Neu-P11 DMIQDFW Alzheimer disease 8A20 Phase 2 [22]
FKB01MD DM2O7NM N. A. N. A. Phase 2 [23]
NXN-188 DMMBAIH Migraine 8A80 Phase 2 [17]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 5A receptor (HTR5A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [24]
(+/-)-nantenine DM0L3GE Discovery agent N.A. Investigative [25]
Serotonin DMOFCRY Discovery agent N.A. Investigative [26]
TFMPP DMAC8TP Discovery agent N.A. Investigative [27]
5,6-dichloro-3,4-dihydroquinazolin-2-amine DMN1S35 Discovery agent N.A. Investigative [28]
MPDT DMYX31S Discovery agent N.A. Investigative [29]
5-chloro-3,4-dihydroquinazolin-2-amine DMKEFJ0 Discovery agent N.A. Investigative [28]
EDMT DMS3AXK Discovery agent N.A. Investigative [29]
5-chloro-4-methyl-3,4-dihydroquinazolin-2-amine DM7FZU2 Discovery agent N.A. Investigative [28]
[3H]5-CT DMEAHFZ Discovery agent N.A. Investigative [30]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 6 receptor (HTR6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
LU AE58054 DMWGRQD Schizophrenia 6A20 Phase 3 [31]
SB-742457 DM6L4ZT Alzheimer disease 8A20 Phase 3 [32]
AVN 211 DMVB4OS Schizophrenia 6A20 Phase 2/3 [33]
SYN120 DMDF7XB Parkinson disease 8A00.0 Phase 2 [34]
AVN 101 DMJFLBC Alzheimer disease 8A20 Phase 2 [33]
SYN-120 DMPW0UL Alzheimer disease 8A20 Phase 2 [35]
PF-05212377 DMPVQYR Alzheimer disease 8A20 Phase 2 [36]
AVN 322 DMK2LGM Cognitive impairment 6D71 Phase 2 [32]
SAM-531 DMHVJZ6 Alzheimer disease 8A20 Phase 2 [37]
SUVN-502 DMQD753 Alzheimer disease 8A20 Phase 2 [38]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 2B receptor (HTR2B)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [7]
Triflupromazine DMKFQJP Psychotic disorder 6A20-6A25 Approved [39]
Minaprine DM0EP7M Depression 6A70-6A7Z Approved [40]
SPN-812 DMTV7XH Attention deficit hyperactivity disorder 6A05.Z Phase 4 [41]
Vabicaserin DM9GZW6 Psychotic disorder 6A20-6A25 Phase 2 [42]
PRX-08066 DMR7H2V Pulmonary arterial hypertension BB01.0 Phase 2 [43]
Pyrimidine derivative 29 DMVOYJ8 N. A. N. A. Patented [44]
Pyrimidine derivative 26 DM90WKN N. A. N. A. Patented [44]
Pyrimidine derivative 23 DM5MLQU N. A. N. A. Patented [44]
Pyrimidine derivative 25 DM51MFS N. A. N. A. Patented [44]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 2A receptor (HTR2A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [7]
Zotepine DMF3VXA Anxiety disorder 6B00-6B0Z Approved [45]
Iloperidone DM6AUFY Schizophrenia 6A20 Approved [46]
Flibanserin DM70DTN Mood disorder 6A60-6E23 Approved [47]
Lurasidone hydrochloride DMCVPXO Schizophrenia 6A20 Approved [48]
Aniracetam DMOIFW0 Cerebrovascular ischaemia 8B1Z Approved [49]
lumateperone tosylate DMQ8HOJ Schizophrenia 6A20 Approved [50]
Sarpogrelate DMGLP6S Diabetic complication 5A2Y Approved [51]
Pimavanserin DMR7IVC Parkinson disease 8A00.0 Approved [52]
Zicronapine DMP8ESD Schizophrenia 6A20 Phase 3 [53]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 1F receptor (HTR1F)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [6]
Lasmiditan DMXLVDT Migraine 8A80 Approved [54]
LY-334370 DM43O9N Migraine 8A80 Phase 2 [55]
TFMPP DMAC8TP Discovery agent N.A. Investigative [56]
1-naphthylpiperazine DM6BIWK Discovery agent N.A. Investigative [6]
BRL-15572 DMM61Y2 Discovery agent N.A. Investigative [57]
2-methyl-5-HT DM1S5CB N. A. N. A. Investigative [56]
alpha-methyl-5-HT DMCAYXF Discovery agent N.A. Investigative [56]
WAY-466 DMMOH51 Discovery agent N.A. Investigative [58]
[125I]LSD DMP69QG Discovery agent N.A. Investigative [59]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 1A receptor (HTR1A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Trazodone DMK1GBJ Depression 6A70-6A7Z Approved [14]
Buspirone DMBS632 Anxiety disorder 6B00-6B0Z Approved [60]
OPC-34712 DMHG57U Major depressive disorder 6A70.3 Approved [61]
Vilazodone DM4LECQ Major depressive disorder 6A70.3 Approved [62]
Flibanserin DM70DTN Mood disorder 6A60-6E23 Approved [47]
Tertatolol DM2L3D5 Hypertension BA00-BA04 Approved [63]
Urapidil DMD59GI Hypertension BA00-BA04 Approved [64]
Treximet DMU54QB Migraine 8A80 Approved [65]
CM-2395 DMASPWR Schizophrenia 6A20 Phase 3 [66]
Eltoprazine DMW6C81 Attention deficit hyperactivity disorder 6A05.Z Phase 3 [16]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 7 receptor (HTR7)
Drug Name Drug ID Indication ICD 11 Highest Status REF
RP5063 DMKUE8O Schizophrenia 6A20 Phase 2 [23]
JNJ-18038683 DMV1T59 Major depressive disorder 6A70.3 Phase 2 [67]
AVN-101 DMOGFNI Cognitive impairment 6D71 Phase 2 [68]
ATI-9242 DM6GKMU Schizophrenia 6A20 Phase 1 [69]
PMID30124346-Compound-34TABLE4 DM2G3VE Attention deficit hyperactivity disorder 6A05.Z Patented [70]
PMID30124346-Compound-13TABLE4 DMHTJVA Attention deficit hyperactivity disorder 6A05.Z Patented [70]
Carbamide derivative 2 DMW5GI3 N. A. N. A. Patented [71]
4-oxadiazole derivative 1 DMWFHKR N. A. N. A. Patented [71]
SB-269970 DM8WTGA Sleep-wake disorder 7A00-7B2Z Terminated [72]
4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one DMM9X0G Discovery agent N.A. Investigative [73]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 2C receptor (HTR2C)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [7]
Lorcaserin DMG6OYJ Obesity 5B81 Approved [74]
Tramadol DMRQD04 Pain MG30-MG3Z Approved [75]
Mirtazapine DML53ZJ Depression 6A70-6A7Z Approved [76]
Nefazodone DM4ZS8M Major depressive disorder 6A70.3 Approved [77]
Methysergide DM1EF73 Migraine 8A80 Approved [78]
Eltoprazine DMW6C81 Attention deficit hyperactivity disorder 6A05.Z Phase 3 [16]
M100907 DM7ZFBA Sleep-wake disorder 7A00-7B2Z Phase 3 [79]
SR46349B DM1ODMR Primary insomnia 7A00 Phase 3 [80]
Vabicaserin DM9GZW6 Psychotic disorder 6A20-6A25 Phase 2 [42]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 1E receptor (HTR1E)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [5]
TFMPP DMAC8TP Discovery agent N.A. Investigative [5]
1-naphthylpiperazine DM6BIWK Discovery agent N.A. Investigative [5]
BRL-15572 DMM61Y2 Discovery agent N.A. Investigative [57]
2-methyl-5-HT DM1S5CB N. A. N. A. Investigative [56]
alpha-methyl-5-HT DMCAYXF Discovery agent N.A. Investigative [5]
m-chlorophenylpiperazine DMM1J2D Discovery agent N.A. Investigative [5]
EDMT DMS3AXK Discovery agent N.A. Investigative [29]
9-OH-risperidone DMGORXQ Discovery agent N.A. Investigative [81]
[3H]5-HT DMYJXV7 Discovery agent N.A. Investigative [82]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 1A receptor (HTR1A) TTSQIFT 5HT1A_HUMAN Agonist [2]
5-HT 1B receptor (HTR1B) TTK8CXU 5HT1B_HUMAN Agonist [3]
5-HT 1D receptor (HTR1D) TT6MSOK 5HT1D_HUMAN Agonist [4]
5-HT 1E receptor (HTR1E) TTCPG9S 5HT1E_HUMAN Agonist [5]
5-HT 1F receptor (HTR1F) TT0MI3F 5HT1F_HUMAN Agonist [6]
5-HT 2A receptor (HTR2A) TTJQOD7 5HT2A_HUMAN Agonist [7]
5-HT 2B receptor (HTR2B) TT0K1SC 5HT2B_HUMAN Agonist [8]
5-HT 2C receptor (HTR2C) TTWJBZ5 5HT2C_HUMAN Agonist [9]
5-HT 5A receptor (HTR5A) TTRUFDT 5HT5A_HUMAN Agonist [10]
5-HT 6 receptor (HTR6) TTJS8PY 5HT6R_HUMAN Agonist [11]
5-HT 7 receptor (HTR7) TTO9X1H 5HT7R_HUMAN Agonist [12]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4).
2 Agonist activity of antimigraine drugs at recombinant human 5-HT1A receptors: potential implications for prophylactic and acute therapy. Naunyn Schmiedebergs Arch Pharmacol. 1997 Jun;355(6):682-8.
3 Mouse 5HT1B serotonin receptor: cloning, functional expression, and localization in motor control centers. Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):3020-4.
4 Primary structure and functional characterization of a human 5-HT1D-type serotonin receptor. Mol Pharmacol. 1991 Aug;40(2):143-8.
5 Molecular cloning and pharmacological characterization of the guinea pig 5-HT1E receptor. Eur J Pharmacol. 2004 Jan 26;484(2-3):127-39.
6 Cloning and characterization of the guinea pig 5-HT1F receptor subtype: a comparison of the pharmacological profile to the human species homolog. Neuropharmacology. 1997 Apr-May;36(4-5):569-76.
7 Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
8 Pharmacological characteristics of the newly cloned rat 5-hydroxytryptamine2F receptor. Mol Pharmacol. 1993 Mar;43(3):419-26.
9 Agonist high and low affinity state ratios predict drug intrinsic activity and a revised ternary complex mechanism at serotonin 5-HT(2A) and 5-HT(2C) receptors. Synapse. 2000 Feb;35(2):144-50.
10 Expression of functional mouse 5-HT5A serotonin receptor in the methylotrophic yeast Pichia pastoris: pharmacological characterization and localization. FEBS Lett. 1995 Dec 27;377(3):451-6.
11 Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor. J Neurochem. 1996 Jan;66(1):47-56.
12 Molecular cloning of a mammalian serotonin receptor that activates adenylate cyclase. Mol Pharmacol. 1993 Aug;44(2):229-36.
13 Two amino acid differences in the sixth transmembrane domain are partially responsible for the pharmacological differences between the 5-HT1D beta and 5-HT1E 5-hydroxytryptamine receptors. J Neurochem. 1996 Nov;67(5):2096-103.
14 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
15 Triptans in pregnancy. Ther Drug Monit. 2008 Feb;30(1):5-9.
16 Clinical pipeline report, company report or official report of Jazz Pharmaceuticals.
17 Company report (NeurAxon)
18 5-HT1B and other related serotonergic proteins are altered in APPswe mutation. Neurosci Lett. 2015 May 6;594:137-43.
19 Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs. 2001;61(3):317-32.
20 An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Proc West Pharmacol Soc. 2002;45:199-210.
21 Efficacy and tolerability of subcutaneous almotriptan for the treatment of acute migraine: a randomized, double-blind, parallel-group, dose-finding study. Clin Ther. 2001 Nov;23(11):1867-75.
22 Clinical pipeline report, company report or official report of Neurim Pharmaceuticals.
23 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
24 Cloning and characterisation of the human 5-HT5A serotonin receptor. FEBS Lett. 1994 Dec 5;355(3):242-6.
25 Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31.
26 Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity. J Med Chem. 2008 Jul 24;51(14):4150-69.
27 Mouse 5-hydroxytryptamine5A and 5-hydroxytryptamine5B receptors define a new family of serotonin receptors: cloning, functional expression, and chromosomal localization. Mol Pharmacol. 1993 Mar;43(3):313-9.
28 Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61.
29 2-Substituted tryptamines: agents with selectivity for 5-HT(6) serotonin receptors. J Med Chem. 2000 Mar 9;43(5):1011-8.
30 Human 5-HT(5) receptors: the 5-HT(5A) receptor is functional but the 5-HT(5B) receptor was lost during mammalian evolution. Eur J Pharmacol. 2001 Apr 27;418(3):157-67.
31 Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats. Int J Neuropsychopharmacol. 2010 Sep;13(8):1021-33.
32 5-HT6 receptors and Alzheimer's disease. Alzheimers Res Ther. 2013; 5(2): 15.
33 Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea. Curr Opin Investig Drugs. 2010 January; 11(1): 80-91.
34 Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs. Nat Rev Drug Discov. 2018 Nov;17(11):804-822.
35 The Serotonin-6 Receptor as a Novel Therapeutic Target. Exp Neurobiol. 2011 December; 20(4): 159-168.
36 PF-05212377 Alzheimer's Disease (Phase 2). Pfizer.
37 Activation of 5-HT6 receptors modulates sleep-wake activity and hippocampal theta oscillation. ACS Chem Neurosci. 2013 Jan 16;4(1):191-9.
38 Novel and Potent 5-Piperazinyl Methyl-N1-aryl Sulfonyl Indole Derivatives as 5-HT6 Receptor Ligands. ACS Med Chem Lett. 2010 October 14; 1(7): 340-344.
39 Some properties of 5-hydroxytryptamine receptors in the hindquarters of the rat. Br J Pharmacol. 1979 Sep;67(1):79-85.
40 Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.
41 New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties. J Exp Pharmacol. 2020 Aug 25;12:285-300.
42 Prediction of Efficacy of Vabicaserin, a 5-HT2C Agonist, for the Treatment of Schizophrenia Using a Quantitative Systems Pharmacology Model.CPT Pharmacometrics Syst Pharmacol.2014 Apr 23;3:e111.
43 Emerging treatments for pulmonary arterial hypertension. Expert Opin Emerg Drugs. 2006 Nov;11(4):609-19.
44 Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
45 Current and novel approaches to the drug treatment of schizophrenia. J Med Chem. 2001 Feb 15;44(4):477-501.
46 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
47 Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
48 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
49 Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol. 2001 May 18;420(1):33-43.
50 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
51 Beneficial effects of sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, supplemented with pioglitazone on diabetic model mice. Endocr Res. 2009;34(1-2):18-30.
52 Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day.Schizophr Res.2012 Nov;141(2-3):144-52.
53 Clinical pipeline report, company report or official report of Lundbeck.
54 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
55 Selective seratonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial. Lancet. 2001 Oct 13;358(9289):1230-4.
56 Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase. Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):408-12.
57 SB-216641 and BRL-15572--compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol. 1997 Sep;356(3):312-20.
58 Discovery of 5-arylsulfonamido-3-(pyrrolidin-2-ylmethyl)-1H-indole derivatives as potent, selective 5-HT6 receptor agonists and antagonists. J Med Chem. 2005 Jan 27;48(2):353-6.
59 Isolation of a mouse "5HT1E-like" serotonin receptor expressed predominantly in hippocampus. J Biol Chem. 1992 Oct 5;267(28):19761-4.
60 Interactions between corticotropin-releasing hormone and serotonin: implications for the aetiology and treatment of anxiety disorders. Handb Exp Pharmacol. 2005;(169):181-204.
61 Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors.Pharmacol Biochem Behav.2014 Sep;124:245-9.
62 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
63 Synthesis of new derivatives of 8-OH-DPAT: Influence of substitution on the aromatic ring on the pharmacological profile, Bioorg. Med. Chem. Lett. 3(10):2035-2038 (1993).
64 Urapidil. A reappraisal of its use in the management of hypertension. Drugs. 1998 Nov;56(5):929-55.
65 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
66 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127)
67 Selective pharmacological blockade of the 5-HT7 receptor attenuates light and 8-OH-DPAT induced phase shifts of mouse circadian wheel running activity. Front Behav Neurosci. 2015 Jan 15;8:453.
68 AVN-101: A Multi-Target Drug Candidate for the Treatment of CNS Disorders. J Alzheimers Dis. 2016 May 25;53(2):583-620.
69 Pharmacological characteristics of ATI-9242, a Novel Atypical Antipsychotic. FASEB J, April, 2010, 24(Meeting Abstract Supplement),773.12.
70 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
71 Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58.
72 [(3)H]-SB-269970--A selective antagonist radioligand for 5-HT(7) receptors. Br J Pharmacol. 2000 May;130(2):409-17.
73 Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
74 Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
75 The inhibitory effects of tramadol on 5-hydroxytryptamine type 2C receptors expressed in Xenopus oocytes. Anesth Analg. 2004 May;98(5):1401-6, table of contents.
76 Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulatio... Mol Pharmacol. 2008 Mar;73(3):748-57.
77 Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie. 2005 Sep-Oct;60(5):441-60.
78 Spinal serotonin receptor activation modulates the exercise ventilatory response with increased dead space in goats. Respir Physiol Neurobiol. 2008 May 31;161(3):230-8.
79 Non-basic ligands for aminergic GPCRs: the discovery and development diaryl sulfones as selective, orally bioavailable 5-HT2A receptor antagonists ... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3708-12.
80 SR46349-B, a 5-HT(2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Neuropsychopharmacology. 2002 Sep;27(3):430-41.
81 Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl). 1996 Mar;124(1-2):57-73.
82 Molecular cloning of a serotonin receptor from human brain (5HT1E): a fifth 5HT1-like subtype. Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5517-21.